Trials / Completed
CompletedNCT00088062
STA-5326 in Crohn's Disease Patients
A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 48 (planned)
- Sponsor
- Synta Pharmaceuticals Corp. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STA-5326 |
Timeline
- Start date
- 2004-02-01
- Completion
- 2004-11-01
- First posted
- 2004-07-21
- Last updated
- 2005-06-24
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00088062. Inclusion in this directory is not an endorsement.